Arovella Therapeutics Ltd has released a press release.
Prospectus For Entitlement Offer
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- Entitlement Offer To Raise Approximately $3.56 Million
- Market Update
- Suspension from Official Quotation
- Anagrelide Cancer Patent For Japan
- SUDA Signs Additional Licence With Mitsubishi Tanabe
Later from Arovella Therapeutics
- TGA Approval Granted For ZolpiMist
- Appendix 4C - quarterly
- Anagrelide Cancer Patent For Australia
- Investor Presentation November 2020
- R & D Tax Incentive refund received
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics